Pharmacy Benefit Manager Transparency Act of 2025
- Sponsor
- Sen. Grassley, Chuck [R-IA]
- Committees
- Commerce, Science, and Transportation Committee (primary)
- Last action
- Feb 11, 2025
Bottom line
This bill seeks to curb PBM practices perceived as opaque and anti-competitive, aiming to lower prescription drug costs and increase fairness for pharmacies and health plans through enhanced transparency and stricter prohibitions.
What it actually does
This bill aims to increase transparency and prevent certain unfair and deceptive practices by Pharmacy Benefit Managers (PBMs) in the prescription drug market. It prohibits PBMs from charging health plans more than they reimburse pharmacies for ingredient costs or dispensing fees, from unfairly clawing back payments, and from increasing pharmacy fees to offset federal reimbursement changes. The bill also mandates PBMs to report detailed financial information to the FTC and HHS, establishes whistleblower protections, and grants the FTC and State Attorneys General enforcement powers.
Proponents argue
Proponents argue that PBMs operate with a lack of transparency, allowing them to engage in practices that inflate prescription drug costs for consumers and health plans, while also unfairly reducing reimbursements to pharmacies. They contend that this bill will bring much-needed transparency to the PBM industry, prevent deceptive pricing, ensure fair compensation for pharmacies, and ultimately lead to lower drug costs for patients by eliminating hidden fees and spread pricing.
Opponents contend
Opponents, likely PBMs and their allies, might argue that the bill's provisions could disrupt existing contractual arrangements, increase administrative burdens, and potentially lead to unintended consequences that could raise, rather than lower, drug costs. They might assert that PBMs already provide significant value by negotiating discounts and managing drug benefits efficiently, and that increased regulation could hinder their ability to secure the best prices for health plans and patients.
The bill is relatively concise and its provisions are clearly articulated, making it accessible for an informed reader to understand its core intent and mechanisms within a reasonable timeframe.
Section 2(a)(1)
Prohibition on Spread Pricing
This provision makes it unlawful for a PBM to charge a health plan or payer a different amount for a prescription drug's ingredient cost or dispensing fee than the amount the PBM reimburses a pharmacy, where the PBM retains the difference. This practice is commonly known as 'spread pricing'.
Supporters argue
Supporters argue this eliminates a key opaque practice where PBMs profit by charging health plans more than they pay pharmacies, without adding value, thereby driving up healthcare costs.
Critics contend
PBMs might argue that spread pricing is a legitimate business practice that allows them to manage risk and provide predictable pricing to health plans, and that its prohibition could lead to less flexibility and potentially higher administrative costs.
Tradeoffs
The tension is between PBMs' ability to generate revenue through spread pricing and the desire of health plans and pharmacies for greater transparency and cost alignment.
Section 2(a)(2)
Prohibition on Unfair Clawbacks
This provision prohibits PBMs from arbitrarily, unfairly, or deceptively reducing, rescinding, or clawing back reimbursement payments to pharmacies for ingredient costs or dispensing fees. Exceptions are allowed only for fraudulent claims, payments inconsistent with contract terms, or services not rendered.
Section 2(a)(3)
Prohibition on Offsetting Federal Reimbursement Changes
This provision makes it unlawful for PBMs to arbitrarily, unfairly, or deceptively increase fees or lower reimbursement to a pharmacy in order to offset reimbursement changes instructed by the Federal Government under any federally funded health plan.
Section 2(b)
Price Concession Pass-Through and Disclosure Requirements
This section provides exceptions to the prohibitions on spread pricing and offsetting federal reimbursement changes if the PBM passes along 100% of any price concession (rebate, discount) to the health plan or payer, AND provides full disclosure of costs, prices, reimbursements, fees, markups, discounts, and aggregate remuneration from drug manufacturers to health plans, payers, and pharmacies.
Section 3
Prohibition on Reporting False or Misleading Information
This section makes it unlawful for any person to report information related to pharmacy benefit management services to a Federal department or agency if they knew or reasonably should have known it was false or misleading, the information was required by law, and it would affect federal analysis of the PBM market.
Section 4(a)
Annual PBM Reporting to FTC and HHS
This section requires PBMs to annually report detailed financial information to the Federal Trade Commission (FTC) and the Secretary of Health and Human Services (HHS). This includes the aggregate difference between what PBMs are paid by health plans and what they pay pharmacies, aggregate fees/concessions charged to pharmacies, payment clawbacks, explanations for formulary tier changes, and differences in reimbursement/fees between PBM-owned pharmacies and independent pharmacies.
Section 4(b)
FTC Annual Report to Congress and Formulary Study
This section requires the FTC to submit annual reports to Congress summarizing enforcement actions, investigations, complaints, anonymized PBM reports, and an analysis of whether the Act leads to PBM mergers and their competitive impact. It also mandates a separate report on PBM formulary design practices, specifically whether they increase PBM gross revenue without increasing patient access or decreasing cost, and recommendations for legislative action.
Section 5
Protections for Whistleblowers
This section prohibits PBMs, health plans, pharmaceutical manufacturers, pharmacies, or their affiliates from retaliating against current or former employees, contractors, or agents who report suspected violations of this Act to Congress, federal/state agencies, or within their organization, or who participate in investigations. It also allows individuals to bring civil actions for relief, including reinstatement and double back pay, and invalidates predispute arbitration agreements for these disputes.
Section 6(a)
FTC Enforcement and Penalties
This section treats violations of the Act as unfair or deceptive acts or practices under the Federal Trade Commission Act, granting the FTC full enforcement powers, including jurisdiction over non-profit organizations and the business of insurance. It also imposes an additional civil penalty of up to $1,000,000 per violation, with each day of a continuing violation considered separate, and courts considering seriousness, efforts to remedy, and intentionality.
Section 6(b)
State Enforcement and Affirmative Defense
This section allows State Attorneys General (or other authorized state officials) to bring civil actions on behalf of their residents for violations of the Act, with requirements for notifying the FTC and allowing FTC intervention. It also provides an affirmative defense for defendants in Section 2 actions if the conduct was nonpretextual and reasonably necessary to prevent a violation of law, protect patient safety, or protect patient access.
This clause explicitly extends the FTC's enforcement authority under this Act to 'organizations not organized to carry on business for their own profit or that of their members' and to 'the business of insurance, and persons engaged in such business,' notwithstanding existing jurisdictional limitations in the Federal Trade Commission Act or the McCarran-Ferguson Act.
Section 6(a)(2)(C)
Why it matters:This is standard legislative practice for clarifying jurisdictional scope, especially when overriding existing statutes. It's technically phrased but highly consequential.
Case for: Supporters would argue this is essential to prevent PBMs from structuring themselves as non-profits or operating within the insurance business to evade FTC oversight, ensuring comprehensive enforcement across the entire PBM market.
Case against: Critics might argue that this expands federal regulatory reach into areas traditionally regulated by states (like insurance) or into non-profit operations without sufficient justification, potentially creating regulatory overlap or burden.
Estimated impact: Significantly broadens the scope of FTC enforcement, ensuring that PBMs cannot use organizational structure or affiliation with insurance companies to escape the Act's provisions.
This section states that nothing in this Act shall be construed to preempt, displace, or supplant any State laws, rules, regulations, or requirements, or the enforcement thereof.
Section 8
Why it matters:This is a standard legislative practice to clarify the relationship between federal and state law, particularly in areas where states have existing regulatory frameworks. It's consequential because it preserves state authority.
Case for: Supporters argue this is crucial for allowing states to continue their own efforts to regulate PBMs and protect consumers, potentially enacting stronger or more tailored regulations than the federal baseline. It prevents the federal law from becoming a ceiling rather than a floor.
Case against: Some industry groups might prefer federal preemption to avoid a 'patchwork' of state regulations, arguing that a single, consistent federal standard would reduce compliance costs and administrative complexity.
Estimated impact: Preserves the ability of states to regulate PBMs, potentially leading to diverse and evolving regulatory landscapes across different states, in addition to federal oversight.